Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 14/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 14/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22327549 | 0.84 | MCL1 (0.47) | MCL1ARNPC1LMNAMAPK1 | |
| SCHEMBL19464683 | 0.82 | MCL1 (0.46) | MCL1ARNPC1LMNAMAPK1 | |
| SCHEMBL495417 | 0.82 | TRPV4 (0.52) | TRPV4ARCYP11B1CYP11B2 | |
| SCHEMBL22023207 | 0.81 | TRPV4 (0.41) | TRPV4ARCYP11B1CYP11B2 | |
| SCHEMBL26124467 | 0.80 | TRPV4 (0.50) | TRPV4ARCYP11B1CYP11B2 | |
| SCHEMBL22021978 | 0.80 | TRPV4 (0.43) | TRPV4ARCYP11B1CYP11B2 | |
| SCHEMBL21466386 | 0.79 | AR (0.58) | TRPV4MCL1ARNPC1LMNA | |
| SCHEMBL6474353 | 0.79 | AR (0.49) | TRPV4ARCYP11B1CYP11B2 | |
| SCHEMBL13496391 | 0.77 | NPC1 (0.46) | NPC1LMNAMAPK1CASP3RAB9A | |
| SCHEMBL26394780 | 0.76 | TRPV4 (0.46) | TRPV4ARCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012463-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | ASSEMBLY BIOSCIENCES INC (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012463-A1 | CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME | HCCS, HAVCR2, SLC10A1 | TRPV4 4698/4885MCL1 1478/4885AR 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.